A molecular stabiliser of an inhibitory eIF2B-eIF2(αP) complex activates the Integrated Stress Response.

Saved in:
Bibliographic Details
Title: A molecular stabiliser of an inhibitory eIF2B-eIF2(αP) complex activates the Integrated Stress Response.
Authors: Shilliday F; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK. fiona.shilliday@astrazeneca.com., Gancedo-Rodrigo M; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., George G; Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK., Aibara S; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Adhikari S; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Ashraf SN; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Barrey EJ; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Centrella PA; X-Chem Inc., Waltham, Massachusetts, USA., Crowther D; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Dickson P; X-Chem Inc., Waltham, Massachusetts, USA., Gikunju D; X-Chem Inc., Waltham, Massachusetts, USA., Guié MA; X-Chem Inc., Waltham, Massachusetts, USA., Guilinger JP; X-Chem Inc., Waltham, Massachusetts, USA., Gunnarsson A; Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Harding HP; Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK., Hupp CD; X-Chem Inc., Waltham, Massachusetts, USA., Jetson R; X-Chem Inc., Waltham, Massachusetts, USA., Keefe AD; X-Chem Inc., Waltham, Massachusetts, USA., Kim JM; Neuroscience, R&D, AstraZeneca, Cambridge, UK., Lewis RJ; Department of Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Maia de Oliveira T; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Le-Marshall J; X-Chem Inc., Waltham, Massachusetts, USA., Narayanan U; X-Chem Inc., Waltham, Massachusetts, USA., Nugai KA; X-Chem Inc., Waltham, Massachusetts, USA., Petrović D; Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Rivers E; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Ron D; Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK., Stringfellow D; Neuroscience, R&D, AstraZeneca, Cambridge, UK., Syson K; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Ward L; Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Yeoman JTS; X-Chem Inc., Waltham, Massachusetts, USA., Yu Y; X-Chem Inc., Waltham, Massachusetts, USA., Zhang Y; X-Chem Inc., Waltham, Massachusetts, USA., Zyryanova A; Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK., Baker DJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., Breccia P; Neuroscience, R&D, AstraZeneca, Cambridge, UK., Linley JE; Neuroscience, R&D, AstraZeneca, Cambridge, UK.
Source: Nature communications [Nat Commun] 2026 May 06. Date of Electronic Publication: 2026 May 06.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-026-72688-y